LEXEO THERAPEUTICS IN

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

13 نوفمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

30 أكتوبر 2024 06:14:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

22 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

05 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

12 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

15 يوليو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

11 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

08 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

09 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

07 مايو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

22 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy

16 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

13 مارس 2024 16:22:39 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

11 مارس 2024 07:42:39 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

11 مارس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

05 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

18 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

11 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire